2014年9月20日（星期六）上午

Saturday Morning, Sept.20^th, 2014

US CACA-CSCO新药研究与评价论坛

（Investigation and Evaluation of Novel Agent Symposium - US CACA-CSCO）

Subject: Breakthrough Cancer Medicines: Scientific and Practical Considerations

        突破性抗癌药物：科学与实践的思考

Venue: 1B Meeting Room, 1st Floor, Xiamen International Conference Center

Co-Chairs: Jian Ding丁  健

           Helen Chen 

           Li Yan 严  立

Keynote Speech

08:30~08:40  Opening Remark 开场致辞

            Jian Ding 丁  健   Shanghai Institute of Materia Medica (SIMM), CAS, China

            Li Yan 严  立   US Chinese Anti-Cancer Association (US CACA)

08:40~08:55  Overview of global landscape in cancer drug R&D全球抗癌药物研发概览

            Helen Chen   National Cancer Institute, USA

08:55~09:10  Zykadia (ceritinib), a 2nd Generation ALK Inhibitor for Patients with ALK+ NSCLC.  二代ALK抑制剂Zykadia (ceritinib)于ALK融合基因非小细胞肺癌的研发与治疗

            Michael Shi   Novartis Company

09:10~09:25  Imbruvica (ibrutinib), a BTK inhibitor for patients with B cell malignancies.  BTK 抑制剂Imbruvica (ibrutinib) 于B细胞白血病的研发与治疗

            Mann Fung 冯文昌   Janssen Pharmaceutical R&D, Johnson & Johnson

09:25~09:40  Palbociclib, a CDK4/6 Inhibitor in development for patients with ER+/HER2- breast cancer.  CDK4/6 抑制剂Palbociclib，针对ER阳性/HER2阴性乳腺癌的研发

            Maria Koehler   Pfizer Company

09:40~09:55  US FDA Breakthrough Designation 美国FDA突破性药物的审阅过程

            Ke Liu 刘  克   Food and Drug Administration (FDA), USA

09:55~10:10  Advancement of new anticancer drug clinical studies in Europe 欧洲抗癌新药临床研究的进展

            Jean Pierre Armand   Institute Gustave-Roussy (IGR), French

10:10~10:20  Discussion

            Li Yan 严  立   US Chinese Anti-Cancer Association (US CACA)

10:20~10:30  Q&A

10:30~10:45  Lucitanib, a multi-kinase inhibitor of FGFR1/2, VEGFR1-3, and PDGFR A/B, in development for patients with solid tumors in China.  Lucitanib, 针对中国实体肿瘤病人研发的FGFR1/2, VEGFR1-3, and PDGFR A/B多靶点抑制剂

            Jian Ding 丁  健   Shanghai Institute of Materia Medica (SIMM), CAS, China

10:45~11:00  AC0010MA, a 3rd Generation Wild-type Sparing EGFR Inhibitor, for Patients of NSCLC with EGFRmut and Acquired T790M Mutation.  AC0010MA,针对EGFR突变/获得性T790M 突变非小细胞肺癌病人的第三代 EGFR 抑制剂

            Xiao Xu   ACEA Biosciences Inc.

11:00~11:15  In China, for China: case study of Apatinib, a VEGFR-2 inhibitor 在中国为中国: Apatinib VEGFR-2 抑制剂研发案例分享

            Li Xu 徐  莉   Jiangsu Hengrui Medicine Co., Ltd.

11:15~11:25  Discussion

            Roger Luo   Janssen Pharmaceutical R&D, Johnson & Johnson

11:25~11:55  Panel Discussion by the co-chairs